Review Article
Gefitinib in Non Small Cell Lung Cancer
Table 5
Ongoing phase III/IV studies in NSCLC.
| Study phase | Line of treatment | ClinicalTrials.gov ID | Setting | Estimated sample size (pts) | Treatment | Primary endpoint |
| III | 1st | NCT00770588 | Maintenance after first line platinum-based chemotherapy | 296 | Gefitinib 250 mg versus Placebo | Progression-free survival | III | 1st | NCT00144066 | Maintenance after first line platinum-based chemotherapy | 600 | Gefitinib 250 mg versus Placebo | Overall survival | IV | 1st | NCT01203917 | Selected Caucasian pts | 100 | Gefitinib 250 mg | Objective response rate | III | ≥2nd | NCT01066195 | Never smoker pts with adenocarcinoma | 129 | Gefitinib 250 mg versus Pemetrexed | Progression-free survival | III | 1st | NCT01017874 | Selected East Asian pts | 226 | Gefitinib alone versus Cisplatin-PemetrexedGefitinib | Progression-free survival | IV | 1st | NCT00173524 | First line Asian pts | 200 | Gefitinib versus Platinum-based chemotherapy | Cost-effectiveness |
| | | | | | Systemic and radiant | | III | 1st-2nd | NCT00955695 | Never smoker adenocarcinoma pts treated with prophylactic cranial irradiation | 242 | Prophylactic whole brain radiation therapy during gefitinib 250 mg or erlotinib 150 mg | Incidence of symptomatic brain metastases |
|
|